Standout Papers

Efficacy and Safety of Av... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 314 citations Mary L. Disis, Matthew H. Taylor et al. JAMA Oncology profile →

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 58 hit
Sub-graph 1 of 20

Citing Papers

Gastric cancer
2025 Hit
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Hit
4 intermediate papers

Works of Jorge Chaves being referenced

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
2021
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
2019 Hit
and 3 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jorge Chaves 905 364 281 210 208 41 1.2k
Jean‐Christophe Sabourin 731 0.8× 420 1.2× 230 0.8× 492 2.3× 177 0.9× 29 1.4k
Corrine Zarwan 685 0.8× 200 0.5× 226 0.8× 318 1.5× 202 1.0× 27 1.1k
Antonio Febbraro 647 0.7× 314 0.9× 108 0.4× 249 1.2× 173 0.8× 56 1.2k
Alexandra S. Zimmer 808 0.9× 338 0.9× 190 0.7× 362 1.7× 200 1.0× 24 1.1k
Zanete Zvirbule 848 0.9× 503 1.4× 88 0.3× 216 1.0× 69 0.3× 45 1.2k
Rodrigo Ruiz‐Soto 431 0.5× 537 1.5× 169 0.6× 159 0.8× 161 0.8× 61 1.3k
Lydia Gaba 773 0.9× 361 1.0× 204 0.7× 508 2.4× 89 0.4× 46 1.4k
Jari Sundström 522 0.6× 296 0.8× 153 0.5× 485 2.3× 95 0.5× 49 1.2k
Ying Zhu 676 0.7× 261 0.7× 142 0.5× 121 0.6× 73 0.4× 28 988
Gregory Friberg 721 0.8× 318 0.9× 89 0.3× 502 2.4× 144 0.7× 35 1.2k

All Works

Loading papers...

Rankless by CCL
2026